Sunshine Biopharma Reports 18% Revenue Growth to $8.9 Million in Q1 2025

Sunshine Biopharma, Inc. reported its financial results for the first quarter of 2025, revealing a revenue of $8.9 million, an 18% increase from $7.5 million in the same period last year. The company's gross profit also rose to $2.73 million, compared to $2.35 million in Q1 2024. Despite the increase in sales, the company incurred a net loss of $1.18 million, or $0.44 per share, which is an improvement from the net loss of $1.28 million, or $2.00 per share, reported in the prior year. The loss from operations decreased slightly from $1.35 million to $1.30 million, indicating a marginal improvement in operational efficiency.

The financial performance reflects strategic developments, including new product launches and enhanced marketing efforts. Sunshine Biopharma has expanded its portfolio to include 70 generic prescription drugs in Canada, with plans to launch an additional 13 products by the end of 2025. The company is also focused on reducing its cost of goods sold, currently at approximately 70%, with a target to lower it to around 60%. This initiative is part of a broader strategy to achieve breakeven and reduce reliance on capital markets for financing.

Operationally, Sunshine Biopharma's cash and cash equivalents stood at $8.12 million as of March 31, 2025, down from $9.69 million at the end of 2024. The company reported a net cash outflow from operating activities of $1.71 million, a significant reduction from $3.19 million in the same quarter of the previous year. This decrease is attributed to lower operational costs at its subsidiary, Nora Pharma. The company also experienced a decline in cash flows from financing activities, which totaled $338,137 in Q1 2025 compared to $5.4 million in the same period last year, primarily due to the absence of significant financing events.

Sunshine Biopharma's strategic focus includes the development of proprietary drugs, such as K1.1 mRNA for liver cancer and SBFM-PL4, a protease inhibitor targeting SARS Coronavirus infections. The company is actively engaged in research and development, with ongoing animal testing for these candidates. Additionally, the company has secured exclusive worldwide licensing agreements for certain technologies related to its antiviral research, further enhancing its product pipeline.

Looking ahead, Sunshine Biopharma aims to leverage its existing cash reserves and revenue generation to fund operations over the next 24 months. The company acknowledges the need for additional capital for future research and development, as well as potential clinical trials. However, it remains optimistic about its growth trajectory, driven by increased sales and operational efficiencies, while also preparing for the challenges of securing future financing.